The Near-Term Setup For Biogen Has Positive Risk/Reward Written All Over It
June 19, 2017 at 15:16 PM EDT
While risks to the stock still remain, UBS has upgraded Biogen Inc (NASDAQ: BIIB) from Sell to Neutral and has raised its price target ...
